Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
International Journal of Clinical Oncology

28-04-2024 | Esophageal Cancer | Original Article

The real-world data of immune-checkpoint inhibitor combination therapy for unresectable or metastatic esophageal cancer: a multi-institutional cohort study

Authors: Sho Sato, Takashi Ssuzuki, Takashi Chinen, Hironori Yamaguchi, Yusuke Suzuki, Nobukazu Hokamura, Zenichiro Saze, Koji Kono, Keita Takahashi, Fumiaki Yano, Chikara Kunisaki, Takashi Kosaka, Itaru Endo, Yasushi Ichikawa, Yutaka Miyawaki, Hiroshi Sato, Hideaki Shimada

Published in: International Journal of Clinical Oncology

Login to get access

Abstract

Background

The real-world efficacy, feasibility, and prognostic factors of immune-checkpoint inhibitor combination therapy for unresectable or metastatic esophageal cancer are not fully established.

Methods

This multi-institutional retrospective cohort study evaluated 71 consecutive patients treated with immune-checkpoint inhibitor combination therapy for esophageal cancer between March 2021 and December 2022. We assessed tumor response, safety, and long-term survival.

Results

In patients with measurable lesions, the response rate was 58%, and the disease control rate for all enrolled patients was 80%. Five patients (7.0%) underwent successful conversion surgery. Grade 3 or higher immune-related adverse events occurred in 13% of patients, and one patient (1.4%) died due to cholangitis. Median progression-free survival was 9.7 (95% confidence interval: 6.5–not reached). C-reactive protein levels and performance status were identified as significant predictors of progression-free survival through Cox proportional hazards analysis.

Conclusions

Immune-checkpoint inhibitor combination therapy for esophageal cancer demonstrated comparable tumor response, safety, and long-term survival to previous randomized clinical trials. Patients with good performance status and low C-reactive protein levels may be suitable candidates for this treatment.
Appendix
Available only for authorised users
Literature
1.
Sung H, Ferlay J, Siegel RL et al (2021) Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin 71:209–249CrossRefPubMed
2.
Lee SJ, Kim S, Kim M et al (2015) Capecitabine in combination with either cisplatin or weekly paclitaxel as a first-line treatment for metastatic esophageal squamous cell carcinoma: A randomized phase II study. BMC Cancer 14(15):693CrossRef
3.
Bleiberg H, Conroy T, Paillot B et al (1997) Randomised Phase II Study of Cisplatin and 5Fluorouracil (5FU) Versus Cisplatin Alone in Advanced Squamous Cell Oesophageal Cancer. Europ J Cancer 33:1216–1220CrossRef
4.
Sun JM, Shen L, Shah MA et al (2021) Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phase 3 study. Lancet 28(398):759–771CrossRef
5.
Doki Y, Ajani JA, Kato K et al (2022) Nivolumab Combination Therapy in Advanced Esophageal Squamous-Cell Carcinoma. N Engl J Med 386:449–462CrossRefPubMed
6.
Shah MA, Kennedy EB, Ashley A-RE et al (2023) Immunotherapy and Targeted Therapy for Advanced Gastroesophageal Cancer: ASCO Guideline. J Clin Oncol 41:1470–1491CrossRefPubMed
7.
Hayashi H, Nakagawa K (2020) Combination therapy with PD-1 or PD-L1 inhibitors for cancer. Int J Clin Oncol 25:818–830CrossRefPubMed
8.
9.
Kelley RK, Ueno M, Yoo C et al (2023) Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 401:1853–1865CrossRefPubMed
10.
Oaknin A, Gladieff L, Martínez-García J et al (2023) Atezolizumab plus bevacizumab and chemotherapy for metastatic, persistent, or recurrent cervical cancer (BEATcc): a randomised, open-label, phase 3 trial. Lancet S0140–6736(23):02405–02414
11.
Satake S, Arigami T, Matsushita D et al (2023) Clinical Significance of Eligibility Criteria Determined by the SPIRITS Trial in Patients with Advanced Gastric Cancer. Oncology 101:12–21CrossRefPubMed
12.
Aoki Y, Kawazoe A, Kubota Y et al (2022) Characteristics and clinical outcomes of patients with advanced gastric or gastroesophageal cancer treated in and out of randomized clinical trials of first-line immune checkpoint inhibitors. Int J Clin Oncol 27:1413–1420CrossRefPubMed
13.
Eisenhauer EA, Therasse P, Bogaerts J et al (2009) New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1) RECIST version 1.1 JCOG ver1.0. Eur J Cancer 45(2):228–247CrossRefPubMed
14.
15.
Zhang L, Ma W, Qiu Z et al (2023) Prognostic nutritional index as a prognostic biomarker for gastrointestinal cancer patients treated with immune checkpoint inhibitors. Front Immunol 14:1219929CrossRefPubMedPubMedCentral
16.
Kojima T, Hara H, Tsuji A et al (2022) First-line pembrolizumab + chemotherapy in Japanese patients with advanced/metastatic esophageal cancer from KEYNOTE-590. Esophagus 19:683–692CrossRefPubMedPubMedCentral
17.
Sato S, Oshima Y, Matsumoto Y et al (2021) The new prognostic score for unresectable or recurrent gastric cancer treated with nivolumab: A multi-institutional cohort study. Ann Gastroenterol Surg 5:794–803CrossRefPubMedPubMedCentral
18.
Gao Y, Zhang Z, Li Y et al (2022) Pretreatment Neutrophil-to-Lymphocyte Ratio as a Prognostic Biomarker in Unresectable or Metastatic Esophageal Cancer Patients With Anti-PD-1 Therapy. Front Oncol 3(12):834564CrossRef
19.
Chang L, Cheng Q, Ma Y et al (2022) Prognostic Effect of the Controlling Nutritional Status Score in Patients With Esophageal Cancer Treated With Immune Checkpoint Inhibitor. J Immunother 45(9):415–422CrossRefPubMedPubMedCentral
20.
Carroll TM, Chadwick JA, Owen RP et al (2023) Tumor monocyte content predicts immunochemotherapy outcomes in esophageal adenocarcinoma. Cancer Cell 41:1222–1241CrossRefPubMed
21.
Yoshida K, Yasufuku I, Terashima M et al (2022) International Retrospective Cohort Study of Conversion Therapy for Stage IV Gastric Cancer 1 (CONVO-GC-1). Ann Gastroenterol Surg 6:227–240CrossRefPubMed
22.
Sato S, Kunisaki C, Tanaka Y et al (2019) Curative-Intent Surgery for Stage IV Advanced Gastric Cancer: Who Can Undergo Surgery and What Are the Prognostic Factors for Long-Term Survival? Ann Surg Oncol 26:4452–4463CrossRefPubMed
23.
Metadata
Title
The real-world data of immune-checkpoint inhibitor combination therapy for unresectable or metastatic esophageal cancer: a multi-institutional cohort study
Authors
Sho Sato
Takashi Ssuzuki
Takashi Chinen
Hironori Yamaguchi
Yusuke Suzuki
Nobukazu Hokamura
Zenichiro Saze
Koji Kono
Keita Takahashi
Fumiaki Yano
Chikara Kunisaki
Takashi Kosaka
Itaru Endo
Yasushi Ichikawa
Yutaka Miyawaki
Hiroshi Sato
Hideaki Shimada
Publication date
28-04-2024
Publisher
Springer Nature Singapore
Published in
International Journal of Clinical Oncology
Print ISSN: 1341-9625
Electronic ISSN: 1437-7772
DOI
https://doi.org/10.1007/s10147-024-02532-0
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits